|Göteborgs universitets publikationer
Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis.
Författare och institution:
John J V McMurray (-); John Kjekshus (-); Lars Gullestad (-); Peter Dunselman (-); Åke Hjalmarson (Wallenberglaboratoriet); Hans Wedel (-); Magnus Lindberg (-); Finn Waagstein (Wallenberglaboratoriet); Peer Grande (-); Jaromir Hradec (-); Gabriel Kamenský (-); Jerzy Korewicki (-); Timo Kuusi (-); François Mach (-); Naresh Ranjith (-); John Wikstrand (Wallenberglaboratoriet)
Circulation, 120 ( 22 ) s. 2188-96
Artikel, refereegranskad vetenskaplig
BACKGROUND: We examined whether the antiinflammatory action of statins may be of benefit in heart failure, a state characterized by inflammation in which low cholesterol is associated with worse outcomes. METHODS AND RESULTS: We compared 10 mg rosuvastatin daily with placebo in patients with ischemic systolic heart failure according to baseline high sensitivity-C reactive protein (hs-CRP) <2.0 mg/L (placebo, n=779; rosuvastatin, n=777) or > or = 2.0 mg/L (placebo, n=1694; rosuvastatin, n=1711). The primary outcome was cardiovascular death, myocardial infarction, or stroke. Baseline low-density lipoprotein was the same, and rosuvastatin reduced low-density lipoprotein by 47% in both hs-CRP groups. Median hs-CRP was 1.10 mg/L in the lower and 5.60 mg/L in the higher hs-CRP group, with higher hs-CRP associated with worse outcomes. The change in hs-CRP with rosuvastatin from baseline to 3 months was -6% in the low hs-CRP group (27% with placebo) and -33.3% in the high hs-CRP group (-11.1% with placebo). In the high hs-CRP group, 548 placebo-treated (14.0 per 100 patient-years of follow-up) and 498 rosuvastatin-treated (12.2 per 100 patient-years of follow-up) patients had a primary end point (hazard ratio of placebo to rosuvastatin, 0.87; 95% confidence interval, 0.77 to 0.98; P=0.024). In the low hs-CRP group, 175 placebo-treated (8.9 per 100 patient-years of follow-up) and 188 rosuvastatin-treated (9.8 per 100 patient-years of follow-up) patients experienced this outcome (hazard ratio, 1.09; 95% confidence interval, 0.89 to 1.34; P>0.2; P for interaction=0.062). The numbers of deaths were as follows: 581 placebo-treated (14.1 per 100 patient-years of follow-up) and 532 rosuvastatin-treated (12.6 per 100 patient-years) patients in the high hs-CRP group (hazard ratio, 0.89; 95% confidence interval, 0.79 to 1.00; P=0.050) and 170 placebo-treated (8.3 per 100 patient-years) and 192 rosuvastatin-treated (9.7 per 100 patient-years) patients in the low hs-CRP group (hazard ratio, 1.17; 95% confidence interval, 0.95 to 1.43; P=0.14; P for interaction=0.026). CONCLUSIONS: In this retrospective hypothesis-generating study, we found a significant interaction between hs-CRP and the effect of rosuvastatin for most end points whereby rosuvastatin treatment was associated with better outcomes in patients with hs-CRP > or = 2.0 mg/L. CLINICAL TRIAL REGISTRATION INFORMATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00206310.
Ämne (baseras på Högskoleverkets indelning av forskningsämnen):
MEDICIN OCH HÄLSOVETENSKAP
Aged, Aged, 80 and over, C-Reactive Protein, metabolism, Cholesterol, HDL, blood, Cholesterol, LDL, blood, Female, Fluorobenzenes, therapeutic use, Heart Failure, Systolic, blood, drug therapy, mortality, Hospitalization, statistics & numerical data, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, therapeutic use, Kaplan-Meiers Estimate, Male, Multicenter Studies as Topic, Pyrimidines, therapeutic use, Randomized Controlled Trials as Topic, Retrospective Studies, Risk Factors, Sulfonamides, therapeutic use, Triglycerides, blood